Waystar Stock Rises 7.0% to $19.84
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 19 2026
0mins
Waystar is up 7.0%, or $1.29 to $19.84.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WAY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WAY
Wall Street analysts forecast WAY stock price to rise
17 Analyst Rating
16 Buy
1 Hold
0 Sell
Strong Buy
Current: 20.220
Low
40.00
Averages
47.81
High
54.00
Current: 20.220
Low
40.00
Averages
47.81
High
54.00
About WAY
Waystar Holding Corp. provides healthcare organizations with mission-critical cloud software that simplifies healthcare payments. The Company’s enterprise-grade platform, Waystar, streamlines the complex processes. It leverages internally developed artificial intelligence (AI) as well as proprietary, advanced algorithms to automate payment-related workflow tasks and drive continuous improvement, which enhances claim and billing accuracy, enriches data integrity, and reduces labor costs for providers. Its software is used daily by providers of all types and sizes across the continuum of care, including physician practices, clinics, surgical centers, and laboratories, as well as large hospitals and health systems. The Company’s clients utilize its software to manage pre-encounter workflows, such as eligibility checks and prior authorization approvals, as well as mid- and post-encounter workflows, such as co-pay collection, claims submission and monitoring, and payer remittances.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Mid-Cap Healthcare Stocks Valuation Analysis
- Valuation Score Overview: According to Seeking Alpha's valuation grades, Acadia Healthcare Company (ACHC) and Waystar Holding (WAY) received an A rating, indicating their attractiveness relative to peers and suggesting potential investor interest for gains.
- Market Performance Highlights: Among mid-cap healthcare stocks with market capitalizations between $2B and $10B, BioCryst Pharmaceuticals (BCRX) stands out with a B+ valuation grade, reflecting its competitiveness and investment appeal in the biopharmaceutical sector.
- Valuation Metrics Analysis: The valuation scores are derived from a comprehensive analysis of multiple metrics, including P/E, PEG, EV/Sales, and EV/EBITDA, providing investors with a robust basis for informed investment decisions.
- Industry Trend Insights: As the healthcare sector continues to evolve, investor focus on mid-cap healthcare stocks is increasing, particularly those demonstrating strong valuation performance, which may attract greater investment inflows in the future.
See More
Waystar CEO to Speak at 46th Annual William Blair Growth Stock Conference
- CEO Speaking Engagement: Waystar's CEO Matt Hawkins is scheduled to speak at the 46th Annual William Blair Growth Stock Conference on June 2, 2026, at 10:40 AM CT, highlighting the company's leadership in healthcare payment software.
- Live Webcast Availability: The presentation will be available via live webcast on Waystar's Investor Relations website, ensuring global investors can access real-time updates and enhancing transparency and investor confidence.
- Extensive Client Base: Waystar serves over 30,000 clients, representing more than 1 million distinct providers, including 16 of the institutions listed in U.S. News Best Hospitals, underscoring its significance and influence in the industry.
- Transaction Processing Capacity: The company processes over 7.5 billion healthcare payment transactions annually, involving over $2.4 trillion in gross claims, covering approximately 60% of U.S. patients and one in three U.S. hospital discharges, demonstrating its critical role in healthcare payments.
See More
Waystar CEO to Speak at William Blair Conference
- Conference Speaking Engagement: Waystar's CEO Matt Hawkins is scheduled to speak at the 46th Annual William Blair Growth Stock Conference on June 2, 2026, at 10:40 a.m. CT, highlighting the company's leadership in healthcare payment software.
- Live Webcast Availability: The presentation will be available via live webcast on Waystar's Investor Relations website, ensuring global investors can access real-time updates and enhancing transparency and investor confidence.
- Extensive Client Base: Waystar serves over 30,000 clients, representing more than 1 million distinct providers, including 16 of the institutions listed in U.S. News Best Hospitals, showcasing its significant influence and market share in the healthcare sector.
- Transaction Processing Capacity: Annually, Waystar processes over 7.5 billion healthcare payment transactions, encompassing over $2.4 trillion in gross claims, covering approximately 60% of U.S. patients and one in three U.S. hospital discharges, underscoring its critical role in healthcare payments.
See More
Waystar Authorizes $200M Stock Repurchase Plan
- Stock Repurchase Plan: Waystar's board has authorized a stock repurchase plan of up to $200 million aimed at enhancing shareholder value through the buyback of common stock, although the plan does not obligate the company to acquire any specific amount of shares.
- Flexibility and Discretion: The repurchase plan allows the company to suspend or discontinue it at any time at its discretion, reflecting the company's flexibility in capital allocation and potential adjustments based on market conditions.
- Stable Revenue Guidance: Waystar projects its 2026 revenue to be between $1.274 billion and $1.294 billion, while adjusting its Q2 sequential growth outlook to flat to a 1% decline, indicating a cautiously optimistic view on future revenues.
- Market Reaction: While the repurchase plan may have a short-term positive impact on stock prices, the company's conservative revenue guidance could raise investor concerns about demand weakness, potentially affecting market confidence.
See More
Waystar Authorized to Repurchase $200 Million in Stock
- Repurchase Authorization: Waystar Holding Corp. announced it has been authorized to repurchase up to $200 million in common stock, aiming to enhance long-term per-share value through a disciplined buyback strategy as market conditions permit.
- Capital Allocation Priorities: CEO Matt Hawkins emphasized that the company's capital allocation priorities remain unchanged, focusing on product innovation and commercial execution to support sustainable growth while maintaining a strong balance sheet.
- Market Reaction: In pre-market trading, Waystar shares rose by 1.29% to $18.79, indicating a positive investor response to the repurchase announcement and reflecting confidence in the company's strategy.
- Long-term Value Commitment: This repurchase authorization not only underscores the company's focus on market valuation but also demonstrates its commitment to returning capital to shareholders at the right time to enhance overall corporate value.
See More
Waystar Q1 2026 Earnings Call Insights
- Significant Revenue Growth: Waystar achieved $314 million in revenue for Q1 2026, reflecting a 22% year-over-year increase, demonstrating strong execution in its healthcare revenue cycle platform and reinforcing its market leadership.
- AI-Driven Market Opportunity: The CEO indicated that the application of AI technology expands Waystar's addressable market from a $20 billion software market to a $100 billion annual revenue cycle labor services market, signaling substantial future growth potential.
- Strong Subscription Revenue: Subscription revenue reached $172 million in Q1, up 38% year-over-year, indicating significant progress in attracting customers and enhancing service quality, which strengthens the company's long-term profitability.
- Adjusted EBITDA Growth: The adjusted EBITDA for Q1 was $135 million, a 26% year-over-year increase, with an EBITDA margin of 43%, primarily driven by a shift to higher-margin solutions, showcasing the company's success in optimizing its cost structure.
See More
Mid-Cap Healthcare Stocks Valuation Analysis
- Valuation Score Overview: According to Seeking Alpha's valuation grades, Acadia Healthcare Company (ACHC) and Waystar Holding (WAY) received an A rating, indicating their attractiveness relative to peers and suggesting potential investor interest for gains.
- Market Performance Highlights: Among mid-cap healthcare stocks with market capitalizations between $2B and $10B, BioCryst Pharmaceuticals (BCRX) stands out with a B+ valuation grade, reflecting its competitiveness and investment appeal in the biopharmaceutical sector.
- Valuation Metrics Analysis: The valuation scores are derived from a comprehensive analysis of multiple metrics, including P/E, PEG, EV/Sales, and EV/EBITDA, providing investors with a robust basis for informed investment decisions.
- Industry Trend Insights: As the healthcare sector continues to evolve, investor focus on mid-cap healthcare stocks is increasing, particularly those demonstrating strong valuation performance, which may attract greater investment inflows in the future.
See More
Waystar CEO to Speak at 46th Annual William Blair Growth Stock Conference
- CEO Speaking Engagement: Waystar's CEO Matt Hawkins is scheduled to speak at the 46th Annual William Blair Growth Stock Conference on June 2, 2026, at 10:40 AM CT, highlighting the company's leadership in healthcare payment software.
- Live Webcast Availability: The presentation will be available via live webcast on Waystar's Investor Relations website, ensuring global investors can access real-time updates and enhancing transparency and investor confidence.
- Extensive Client Base: Waystar serves over 30,000 clients, representing more than 1 million distinct providers, including 16 of the institutions listed in U.S. News Best Hospitals, underscoring its significance and influence in the industry.
- Transaction Processing Capacity: The company processes over 7.5 billion healthcare payment transactions annually, involving over $2.4 trillion in gross claims, covering approximately 60% of U.S. patients and one in three U.S. hospital discharges, demonstrating its critical role in healthcare payments.
See More
Waystar CEO to Speak at William Blair Conference
- Conference Speaking Engagement: Waystar's CEO Matt Hawkins is scheduled to speak at the 46th Annual William Blair Growth Stock Conference on June 2, 2026, at 10:40 a.m. CT, highlighting the company's leadership in healthcare payment software.
- Live Webcast Availability: The presentation will be available via live webcast on Waystar's Investor Relations website, ensuring global investors can access real-time updates and enhancing transparency and investor confidence.
- Extensive Client Base: Waystar serves over 30,000 clients, representing more than 1 million distinct providers, including 16 of the institutions listed in U.S. News Best Hospitals, showcasing its significant influence and market share in the healthcare sector.
- Transaction Processing Capacity: Annually, Waystar processes over 7.5 billion healthcare payment transactions, encompassing over $2.4 trillion in gross claims, covering approximately 60% of U.S. patients and one in three U.S. hospital discharges, underscoring its critical role in healthcare payments.
See More
Waystar Authorizes $200M Stock Repurchase Plan
- Stock Repurchase Plan: Waystar's board has authorized a stock repurchase plan of up to $200 million aimed at enhancing shareholder value through the buyback of common stock, although the plan does not obligate the company to acquire any specific amount of shares.
- Flexibility and Discretion: The repurchase plan allows the company to suspend or discontinue it at any time at its discretion, reflecting the company's flexibility in capital allocation and potential adjustments based on market conditions.
- Stable Revenue Guidance: Waystar projects its 2026 revenue to be between $1.274 billion and $1.294 billion, while adjusting its Q2 sequential growth outlook to flat to a 1% decline, indicating a cautiously optimistic view on future revenues.
- Market Reaction: While the repurchase plan may have a short-term positive impact on stock prices, the company's conservative revenue guidance could raise investor concerns about demand weakness, potentially affecting market confidence.
See More
Waystar Authorized to Repurchase $200 Million in Stock
- Repurchase Authorization: Waystar Holding Corp. announced it has been authorized to repurchase up to $200 million in common stock, aiming to enhance long-term per-share value through a disciplined buyback strategy as market conditions permit.
- Capital Allocation Priorities: CEO Matt Hawkins emphasized that the company's capital allocation priorities remain unchanged, focusing on product innovation and commercial execution to support sustainable growth while maintaining a strong balance sheet.
- Market Reaction: In pre-market trading, Waystar shares rose by 1.29% to $18.79, indicating a positive investor response to the repurchase announcement and reflecting confidence in the company's strategy.
- Long-term Value Commitment: This repurchase authorization not only underscores the company's focus on market valuation but also demonstrates its commitment to returning capital to shareholders at the right time to enhance overall corporate value.
See More
Waystar Q1 2026 Earnings Call Insights
- Significant Revenue Growth: Waystar achieved $314 million in revenue for Q1 2026, reflecting a 22% year-over-year increase, demonstrating strong execution in its healthcare revenue cycle platform and reinforcing its market leadership.
- AI-Driven Market Opportunity: The CEO indicated that the application of AI technology expands Waystar's addressable market from a $20 billion software market to a $100 billion annual revenue cycle labor services market, signaling substantial future growth potential.
- Strong Subscription Revenue: Subscription revenue reached $172 million in Q1, up 38% year-over-year, indicating significant progress in attracting customers and enhancing service quality, which strengthens the company's long-term profitability.
- Adjusted EBITDA Growth: The adjusted EBITDA for Q1 was $135 million, a 26% year-over-year increase, with an EBITDA margin of 43%, primarily driven by a shift to higher-margin solutions, showcasing the company's success in optimizing its cost structure.
See More
